1
Clinical Trials associated with Denosumab Biosimilar(Xentria)A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® Sourced From the European Union and United States in Healthy Male Participants
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
100 Clinical Results associated with Denosumab Biosimilar(Xentria)
100 Translational Medicine associated with Denosumab Biosimilar(Xentria)
100 Patents (Medical) associated with Denosumab Biosimilar(Xentria)
100 Deals associated with Denosumab Biosimilar(Xentria)